Yan-hong Li

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities?

What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities?

Journal: Expert opinion on drug metabolism & toxicology

Published: November 24, 2023

Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date.

Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date.

Journal: Expert opinion on pharmacotherapy

Published: October 26, 2023

Evaluating gliclazide for the treatment of type 2 diabetes mellitus.

Evaluating gliclazide for the treatment of type 2 diabetes mellitus.

Journal: Expert opinion on pharmacotherapy

Published: October 27, 2022

Identification of potential immunomodulators from Pulsatilla decoction that act on therapeutic targets for ulcerative colitis based on pharmacological activity, absorbed ingredients, and in-silico molecular docking.

Identification of potential immunomodulators from Pulsatilla decoction that act on therapeutic targets for ulcerative colitis based on pharmacological activity, absorbed ingredients, and in-silico molecular docking.

Journal: Chinese medicine

Published: July 19, 2022

Anemoside B4 protects against chronic relapsing colitis in mice by modulating inflammatory response, colonic transcriptome and the gut microbiota.

Anemoside B4 protects against chronic relapsing colitis in mice by modulating inflammatory response, colonic transcriptome and the gut microbiota.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: June 02, 2022

Anemoside B4 ameliorates experimental autoimmune encephalomyelitis in mice by modulating inflammatory responses and the gut microbiota.

Anemoside B4 ameliorates experimental autoimmune encephalomyelitis in mice by modulating inflammatory responses and the gut microbiota.

Journal: European journal of pharmacology

Published: April 14, 2022

Correction to Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models.

Correction to Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models.

Journal: Journal of natural products

Published: August 18, 2021

Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models.

Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models.

Journal: Journal of natural products

Published: May 21, 2020

Therapeutic potential of triterpenoid saponin anemoside B4 from Pulsatilla chinensis.

Therapeutic potential of triterpenoid saponin anemoside B4 from Pulsatilla chinensis.

Journal: Pharmacological research

Published: May 11, 2020

iTRAQ-based pharmacoproteomics reveals potential targets of berberine, a promising therapy for ulcerative colitis.

iTRAQ-based pharmacoproteomics reveals potential targets of berberine, a promising therapy for ulcerative colitis.

Journal: European journal of pharmacology

Published: December 28, 2018

A characterization of pro-inflammatory cytokines in dextran sulfate sodium-induced chronic relapsing colitis mice model.

A characterization of pro-inflammatory cytokines in dextran sulfate sodium-induced chronic relapsing colitis mice model.

Journal: International immunopharmacology

Published: November 02, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026